Accessibility StatementSkip Navigation The 55,000-Square-Foot Facility is the Latest Addition to Cryoport Systems' Global Supply Chain Center Network "Our new facility in Louvres strengthens Cryoport Systems' Global Supply Chain Center Network significantly and provides us with increased ability to serve our clients in the European and global markets," said Jerrell Shelton, CEO of Cryoport. "By providing integrated capabilities and end-to-end services, we will continue to ensure secure, compliant handling ...

Core Insights - Cryoport, Inc. reported strong financial results for Q2 and H1 2025, with total revenue from continuing operations increasing by 14% year-over-year to $45.5 million in Q2 and 12% to $86.5 million in H1 [10][19][20] - The company achieved double-digit growth across all revenue streams within Life Sciences Services, with a notable 21% increase year-over-year [2][4] - A strategic partnership with DHL Group was launched, enhancing Cryoport's global biologistics capabilities and providing a strong capital infusion [5][10] Financial Performance - Life Sciences Services revenue for Q2 2025 was $24.4 million, up 21% from $20.2 million in Q2 2024, and accounted for 54% of total revenue [19][10] - BioLogistics Solutions revenue increased by 20% year-over-year to $19.9 million, while BioStorage/BioServices revenue rose 28% to $4.5 million [19][10] - Life Sciences Products revenue grew 8% year-over-year to $21.1 million [19][10] Profitability Metrics - Gross margin from continuing operations improved to 47.0% in Q2 2025, compared to 44.5% in Q2 2024 [19][10] - Adjusted EBITDA was a negative $0.9 million for Q2 2025, an improvement from negative $5.6 million in Q2 2024 [21][10] Strategic Developments - The company supported 728 global clinical trials as of June 30, 2025, a net increase of 44 trials from the previous year [7][9] - Cryoport's customer, Abeona Therapeutics, received FDA approval for their cell therapy ZEVASKYNTM during the quarter [9][10] Guidance and Future Outlook - Cryoport reaffirmed its full-year 2025 revenue guidance, expecting total revenue from continuing operations to be in the range of $165 million to $172 million, representing 5% to 10% growth year-over-year [24][10] - The company anticipates additional application filings and therapy approvals in the remainder of 2025 [11][10]

NASHVILLE, Tenn., July 22, 2025 /PRNewswire/ -- Cryoport, Inc. (Nasdaq: CYRX) ("Cryoport" or the "Company"), a global leader in temperature-controlled supply chain solutions for the life sciences, today announced that the Company will report financial results for the second quarter ended June 30, 2025 on Tuesday, August 5, 2025 after U.S. markets close. In addition to the earnings release, a document titled "Cryoport Second Quarter 2025 in Review", providing a review of Cryoport's financial and operational ...

Core Insights - Cryoport, Inc. has completed the divestiture of its specialty courier business, CRYOPDP, to DHL Group for approximately $200 million in cash [1][4] - A strategic partnership has been established between Cryoport and DHL to enhance supply chain services in the global life sciences and healthcare sector [2][3] Financial Impact - The divestiture provides a significant capital infusion, improving Cryoport's growth trajectory and positioning the company for sustainable, long-term profitability [4] Strategic Focus - The partnership with DHL is expected to enhance Cryoport's capabilities in the Asia Pacific and EMEA regions, allowing for targeted services in response to market demand [3] - Cryoport aims to intensify its focus on advancing its Life Science Services platform, particularly in the regenerative medicine market [3] Company Overview - Cryoport is a leader in temperature-controlled supply chain solutions for the life sciences, emphasizing regenerative medicine [5] - The company offers a comprehensive suite of services designed to minimize risk and maximize reliability across the temperature-controlled supply chain [5]

Core Viewpoint - Cryoport, Inc. reported a strong start to 2025 with a revenue of $41.0 million for Q1, reflecting a 10% year-over-year growth, and expressed optimism for the full year due to stabilizing order patterns and increased engagement in its Life Sciences Services segment [2][6][19]. Financial Performance - Total revenue from continuing operations for Q1 2025 was $41.0 million, up from $37.3 million in Q1 2024, marking a 10.1% increase [14]. - Life Sciences Services revenue, which constituted 56% of total revenue, reached $22.9 million, a 17.3% increase year-over-year [14]. - Life Sciences Products revenue, representing 44% of total revenue, was $18.2 million, showing a 2.1% increase compared to the previous year [14]. - Adjusted EBITDA for Q1 2025 was a negative $2.8 million, an improvement from a negative $6.7 million in Q1 2024 [16][38]. - The net loss for Q1 2025 was $12.0 million, compared to a net loss of $18.9 million in Q1 2024 [24]. Business Segments - Revenue from commercial Cell & Gene therapies increased by 33% year-over-year, totaling $7.2 million [8][9]. - Life Sciences Services revenue increased by 17% year-over-year, driven by the development and commercialization of Cell & Gene-based therapies [3][9]. - BioStorage/BioServices revenue grew by 23% year-over-year, indicating strong demand for these services [7]. Strategic Developments - Cryoport announced a strategic partnership with DHL Group, which includes the anticipated acquisition of CRYOPDP, expected to close in Q2 or Q3 2025 [5][11]. - The partnership is expected to enhance operational reach in the APAC and EMEA regions and provide a strong infusion of capital [5][11]. Market Position and Outlook - The company supports 711 global clinical trials as of March 31, 2025, an increase of 36 trials from the previous year [9]. - The company anticipates continued growth in the regenerative medicine space and aims to return to positive adjusted EBITDA during 2025 [6][19].

Conference Call Information | Date: | Wednesday, May 7, 2025 | | --- | --- | | Time: | 5:00 p.m. ET | | Dial-in numbers: | 1-800-717-1738 (U.S.), 1-646-307-1865 (International) | | | Confirmation code:Request the "Cryoport Call" or Conference ID: 1180684 | | | 'Investor Relations' section at www.cryoportinc.com or click here. | | Live webcast: | Please allow 10 minutes prior to the call to visit this site to download and install any | | | necessary audio software. | The questions and answers call will be re ...